最新医学　別冊　新しい診断と治療のABC22　アルツハイマー病

出版社： 最新医学社
発行日： 2004-08-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
電子書籍版： 2004-08-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学　別冊　新しい診断と治療のABC22　アルツハイマー病

    ―目次―

    第１章　アルツハイマー病の概念・定義
    　概念･定義
    　疫学

    第２章　アルツハイマー病の病因･病態生理
    　病理
    　病態発症機序
    　危険因子-遺伝
    　危険因子-環境

    第３章　アルツハイマー病の診断
    　臨床症状、診断基準
    　評価スケール
    　軽度認知障害（MCI)
    　画像診断
    　バイオマーカー
    　新しい画像診断-アミロイドイメージング- 東
    　鑑別診断

    第４章　アルツハイマー病の管理と治療
    　包括管理･診療
    　薬物療法-中核症状
    　薬物療法-周辺症状
    　薬物療法-漢方治療
    　新しい治療法開発-Aβワクチン療法
    　非薬物療法
    　家族介護者の介護負担
    　経過･予後
    　社会資源
    　医療経済

    第５章　アルツハイマー病治療ガイドライン
    　治療ガイドライン

    座談会　アルツハイマー病医療の展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 アルツハイマー病の概念・定義

P.15 掲載の参考文献
1) Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie 64:146-148, 1907.
 
2) Davies P, et al:Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403, 1976.
 
3) American Psychiatric Association:Diagnostic and statistical manual of mental disorders. 4th edition. Washington DC, 1994.
 
4) 三好功峰:老年期の痴呆性疾患, 医学書院, 東京, 1997.
 
5) Knopman D S, et al:Practice parameter:diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academyof Neurology. Neurology 56:1143-1153.
 
P.24 掲載の参考文献
1) Key D W K, et al:Epidemiology of mental disorders among the aged in the community. In:Handbook of Mental Health and Aging, (Birren J E, et al eds) 34-56, Prentice-Hall, Englewood Cliffs, 1980.
 
2) 田尻町保険医療, 福祉の将来構想並びに基本計画策定に関する調査報告書:第I部, 第II部スキップ構想, 第III部計画実地に関する問題点と提言. 宮城県田尻町, 1991年3月.
 
3) Ishizaki J, et al:Anormative, community-based study of Mini-Mental State in elderly adults:the effect of age and educational level. J Gerontol B Psychol Sci Soc Sci 53B:359-363, 1998.
 
4) Ambo H, et al:Depressive symptoms and associated factors in a cognitively normal elderly population:the Tajiri Project. Int J Geriatr Psychiatr 16:780-788, 2001.
 
5) Hughes C P, et al:A new clinical scale for the staging of dementia. Br J Psychiatry 140:566-572, 1982.
PubMed
6) Teng E L, et al:The Cognitive Abilities Screening Instrument (CASI):a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6:45-58, 1994.
 
7) Ishii H, et al:Prevalence of senile dementia in a rural community in Japan:the Tajiri Project. Arch Gerontol Geriatr 29:249-265, 1999.
 
8) Meguro K, et al:Cognitive function and frontal lobe atrophy in normal elderly adults:Implications for dementia not as aging-related disorders and the reserve hypothesis. Psychiatry Clin Neurosci 55:565-572, 2001.
 
9) Meguro K, et al:Prevalence of dementia and dementing diseases in Japan:The Tajiri Project Arch Neurol 59:1109-1114, 2002.
PubMed
10) McKhann G, et al:Clinical diagnosis of Alzheimer's disease:Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944, 1984.
 
11) Roman G C, et al:Vascular dementia:Diagnostic criteria for research studies. Report of the NINDS-AIREN International Work-group. Neurology 43:250-260, 1993.
 
12) Chui H C, et al:Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42:473-480, 1992.
 
13) Pohjasvaara T, et al:Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et al:Enseignement en Neurosciences. Stroke 31:2952-2957, 2000.
 
14) 目黒謙一, 他:血管性痴呆の疫学問題:診断基準の問題点と神経基盤に関する考察. 老年精医誌 14:169-180, 2003.
Medical*Online
15) Ikeda M, et al:Increased prevalence of vascular dementia in Japan:A community-based epidemiological study. Neurology 57:839-844, 2001.
PubMed
16) Kral V A:Senescent forgetfulness:benign and malignant. Can Med Assoc J 86:257-260, 1962.
PubMed
17) Ritchie K, et al:Mild cognitive impairment:Conceptual basis and current nosological status. Lancet 355:225-228, 2000.
PubMed
18) Flicker C, et al:Mild cognitive impairment in the elderly:predictors of dementia. Neurology 41:1006-1009, 1991.
PubMed
19) Smith G E, et al:Definition, course, and outcome of mild cognitive impairment. Age Neuropsychol Cogn 3:141-147, 1996.
 
20) Morris J C, et al:Very mild Alzheimer's disease:Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 41:469-478, 1991.
PubMed
21) Price J L, et al:Tangles and plaques in non-demented aging and "preclinical" Alzheimer's disease. Ann Neurol 45:358-368, 1999.
 
22) Morris J C, et al:Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397-405, 2001.
PubMed
23) Meguro K, et al:Prevalence and cognitive performances of Clinical Dementia Rating and mild cognitive impairment in Japan:The Tajiri Project. Alz Dis Assoc Disord 18:3-10, 2004.
 
24) Mori E, et al:Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Am J Psychiatry 154:18-24, 1997.
 
25) Snowdon D A:Aging and Alzheimer's disease:lessons from the Nun Study. Gerontologist 37:150-156, 1997.
PubMed
26) Meguro K, et al:An environmental change does not affect dementia prevalence but affects depressive sate and physical activity:A trans-cultural study of Japanese elderly subjects and Japanese elderly immigrants in Brazil. Psychogeriatrics 1:295-302, 2001.
PubMed
27) Yamada M, et al:Prevalence and risk of dementia in the Japanese Population:PERP's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc 47:189-195, 1999.
 
28) Hendrie H C, et al:Incidence of dementia and Alzheimer disease in 2 communities. Yoruba residing in Ibadan, Nigeria, and African Americans residing in lndianapolis, Indiana. JAMA 285:739-747, 2001.
PubMed
29) Kivipelto M, et al:Midlife vascular risk factors and Alzheimer's disease in later life:longitudinal, population based study. BMJ 322:1447-1451, 2001.
PubMed
30) Kalmijn S, et al:Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42:776-782, 1997.
PubMed
31) Friedland R P, et al:Premorbid environmental complexity is reduced in patients with Alzheimer's disease (AD) as compared to age-and sex-matched controls:results of case-control study. In:Proceedings of the Fifth International Conference on Alzheimer's Disease and Related Disease. (Iqbal K, et al, eds), 33-37, NY:John Wiley & Sons; New York, 1997.
 
32) Fratiglioni et al:Influence of social network on occurrence of dementia:a community-based longitudinal study. Lancet 355:1315-1319, 2000.
PubMed
33) Ishizaki J, et al:Therapeutic psychosocial intervention for elderly subjects with very mild Alzheimer's disease in a community; the Tajiri Project. Alzheimer Dis Assoc Disord 16:261-269, 2002.
 

第2章 アルツハイマー病の病理・病態生理

P.38 掲載の参考文献
1) 朝長正徳:脳の形態と老化. 脳の老化 (入来正躬, 他 著), p3-59. 共立出版, 東京, 1981.
 
2) 朝長正徳:II病理, アルツハイマー型老年痴呆 (朝長正徳 編著), p117-136. 藤田企画出版, 東京, 1988
 
3) DeArmond S J, et al:Alzheimer's disease. In:Textbook of Neuropathology, Third ed, (Davis RL, et al, eds), p1068-1097. Williams & Wilkins, Philadelphia, 1997.
 
4) Duykaerts C, et al:Neuropathology of Alzheimer's disease. In:Neurodegeneration:The molecular pathology of dementia and movement disorders, p47-65. ISN Neuropath Press, Basel, 2003.
 
5) Haub JJ, et al:Alzheimer's disease. In:Pathology of the aging human nervous system, Second ed. (Duckett S, et al, eds), p207-263, 0xford, 2001.
 
6) Mirra S S, et al:Alzheimer's disease. Greenfield's neuropathology, Seventh ed, (Graham DI, et al, eds), p200-226, Arnold, 2002.
 
7) Price D L, et al:Neuropathology of Alzheimer's disease and animal models. Neuropathology of dementing disorders. (Markesbery W R, eds), p121-141, Arnold, 1988.
 
8) Scheibel M E, et al:The aging human Betz cell. Exp Neurol 56:598-609, Raven, 1975.
 
9) Braak H, et al:Golgi preparation as a tool in neuropathology with particular reference to investigations of the human telencephalic cortex. Prog Neurobiol 25:93, 1985.
 
10) Zhan SS, et al:Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurode-generative disorders with dementia. Dementia 4:66-74, 1993.
 
11) Scheff S W, et al:Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neuro 133:190-199, 1993.
 
12) Terry R D, et al:Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 10:184-192, 1981.
PubMed
13) Pollanen M S, et al:Paired helical filaments are twisted ribbons composed of two parallel and aligned components:image recon-struction and modeling of filament structure using atomic force microscopy. J Neuropathol Exp Neurol 56:79-85, 1997.
 
14) Braak H, et al:Occurrence of neuropil threads in the senile human brain alld in Alzheimer's disease. A third location of paired helical filaments outside of neurofilament tangles and neuritic plaques Neurosci Lett 65:351-355, 1986.
 
15) Bancher C, et al:Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 477:90-99, 1989.
PubMed
16) Braak H, et al:Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol 82:239-259, 1991.
PubMed
17) Delaere P, et al:Subtypes and differential laminar distributions of B A4 deposits in Alzheimer's disease:relationship with the intellectual status of 26 cases. Acta Neuropathol 81:328-335, 1991.
 
18) Chui De-Hua, et al:Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5:560-564, 1999.
 
19) Tomlinson B E, et al:Some quantitative cerebral findings in normal and demented old people. In:Neurobiology of aging (Terry RD, et al, eds), p183, Raven, 1976.
 
P.51 掲載の参考文献
1) Saido T C:Overview-AB metabolism:from Alzheimer research to brain aging control. In:AB Metabolism and Alzheimer's Disease. (ed Saido TC) p1-16. Landes Bioscience, Georgetown, 2003.
 
2) Kayed R, et al:Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (5618):486-489, 2003.
PubMed
3) Saido T C, et al:Proteolytic degradation of AB by neprilysin and other peptidases. In:AB Metabolism and Alzheimer's Disease. (ed Saido TC) p61-80. Landes Bioscience, Georgetown, 2003.
 
4) Higgins G A, et al:Transgenic mouse models of Alzheimer's disease:phenotype and application. Behav Pharmacol 14 (5-6):419-438, 2003.
 
5) Iwata N, et al:Identification of the major AB 1-42-degrading catabolic pathway in brain parenchyma:Suppression leads to biochemical and pathological deposition Nature Med 6 (2):143-151, 2000.
 
6) Iwata N, et al:Metabolic regulation of brain AB by neprilysin. Science 292 (5521):1550-1552, 2001.
 
7) Fukami S, et al:AB-degrading endopeptidase, neprilysin, in mouse brain:synaptic and axonal localization inversely correlating with AB pathology. Neurosci Res 43 (1):39-56, 2002.
 
8) Iwata N, et al:Region-specific reduction of AB-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70 (3):493-500, 2002.
 
9) Yasojima K, et al:Reduced neprilysin in high plaque areas of Aizheimer brain:a possible relationship to deficient degradation of B-amyloid peptide. Neurosci Lett 297 (2):97-100, 2001.
 
10) Wang D S, et al:Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 310 (1):236-241, 2003.
 
11) Tsubuki S, et al:Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of AB to physiologically relevant proteolytic degradation. Lancet 361 (9373):1957-1958, 2003.
 
12) Hsiao K:Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 33 (7-8):883-889, 1998.
 
13) Higuchi M, et al:Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2 (2):131-150, 2002.
PubMed
14) Lewis J, et al:Enhanced neurofibrillary degeneration ln transgenic mice expressing mutant tau and APP. Science 293 (5534):1487-1491, 2001.
 
15) Oddo S, et al:Triple-transgenic model of Alzheimer's disease with plaques and tangles:intracellular AB and synaptic dysfunction. Neuron 39 (3):409-421, 2003.
 
16) Giasson BI, et al:Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (5619):636-640, 2003.
PubMed
17) Reisberg B, et al:Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (14):1333-1341, 2003.
PubMed
18) Nixon R A, et al:Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann NY Acad Sci 747:77-91, 1994.
PubMed
19) Lee M S, et al:Neurotoxicity induces cleav-age of p35 to p25 by calpain. Nature 405 (6784):360-364, 2000.
 
20) Higuchi M, et al:Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35 (3):433-446, 2002.
PubMed
P.62 掲載の参考文献
1) The Human Gene Mutation Database Cardiff http://archive.uwcm.ac.uk/uwcm/mg/hgm0.html
 
2) Selkoe D J:Alzheimer's disease:genotypes, phenotypes, and treatments. Science 275:630-631, 1997,
 
3) 田平 武:プレセニリン遺伝子変異による Alzheimer 病. 日臨 62:90-94, 2004.
Medical*Online
4) 保田 稔:アルツハイマー病の遺伝子診断. Modern Physician 21 (4):429-435, 2001.
 
5) 保田 稔, 他:家族性アルツハイマー病と遺伝子. 臨床精神医学講座 special issue 9巻 アルツハイマー病 (三好功峰, 他), p357-380, 中山書店, 東京, 2000.
 
P.70 掲載の参考文献
1) Christen Y:Oxidative stress and Alzheimer disease. Am J Clin Nutr 71 (suppl):621S-629S, 2000.
 
2) Engelhart, et al:Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 287:3223-3229, 2002.
PubMed
3) Morris M C, et al:Dietary intake of antioxidants nutrients and risk of incident Alzheimer's disease in a biracial community study. JAMA 287:3230-3237, 2002.
 
4) Kalmijn S, et al:Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 42:776-782, 1997.
PubMed
5) Morris M C, et al:Consumption of fish and n-3 fatty acids and risk of incident Alzheimer's disease. Arch Neurol 60:940-946, 2003.
 
6) Pasinetti G M:Cyclooxygenase and inflammation in Alzheimer's isease:experimental approaches and clinical interventions. J Neurosci Res 54:1-6, 1998.
 
7) Puskas L G, et al:Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci USA 100:1580-1585, 2003.
PubMed
8) Gustafson D, et al:An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163:1524-1528, 2003.
PubMed
9) Luchsinger J A, et al:Caloric intake and the risk of Alzheimer disease. Arch Neurol 59:1258-1263, 2002.
PubMed
10) Ott A, et al:Association of diabetes mellitus and dementia:The Rotterdam Study. Diabetologia 39:1392-1397, 1996.
PubMed
11) Craft S, et al:Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease. Relationship to severty of dementia and apolipoprotein E genotype. Neurology 50:164-168, 1998.
 
12) Watson GS, et al:Insulin increases CSF AB42 1evels in normal older adults. Neurology 60:1899-1903, 2003.
 
13) Farris W, et al:Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100:4162-4167, 2003.
PubMed
14) Graves AB, et al:Alcohol and tabacco con-sumption as risk factors for Alzheimer's disease:A collaborativere-analysis of case-control studies. Tnt J Epidemiol 20 (Suppl):S48-57, 1991.
 
15) Ott A, et al:Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study, the Rotterdam study. Lancet 351:1840-1843, 1998.
 
16) Ruitenberg A, et al:Aicohol consumption and risk of dementia:the Rotterdam study. Lancet 359:281-286, 2002.
 
17) Laurin D, et al:Physical activity abd risk of cognitive impairment and dementia in elderly persons. Arch Neurol 58:498-504, 2001.
 
18) Sparks D L, et al:Link between heart disease, choklesterol, and Alzheimer disease:a review. Microsc Res Tech 50:287-290, 2000.
PubMed
19) Forette F, et al:Prevalence of dementia in randomsed double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352:1347-1351, 1998.
 
20) Bremner J D, et al:MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 152:973-981, 1995.
PubMed
21) Harrington C R, et al:Alazheimer's disease-like changes in tau protein Processing association with aluminium accumulation inbrains of renal dialysis patients. Lancet 343:993-997, 1994.
PubMed
22) Kobayashi K, et al:26 Al tracer experiment by accelerator mass spectrometry and its application to the studies for amyotrophic lateral sclerosis and Alazheimer's disease I. Proc Japan Acad Ser B 66:189-192, 1990.
 

第3章 アルツハイマー病の診断

P.82 掲載の参考文献
1) Braak H, et al:Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (4):239-259, 1991.
PubMed
2) 田邊敬貴:痴呆の症候学, 医学書院, 東京, 2000.
 
3) Ikeda M, et al:Delusions of Japanese patients with Alzheimer's disease. Int J Geriatr Psychiatry 18 (6):527-532, 2003.
 
4) Ikeda M, et al:Dementia associated mental and behavioural disturbances in elderly people in the community:findings from the first Nakayama study. J Neurol Neurosurg Psychiatry 75 (1):146-148, 2004.
PubMed
5) 博野信次:臨床痴呆学入門, 金芳堂, 京都, 2001.
 
6) American Psychiatric Association, Diagnostic and Statiscal Manual of Mental Disorders, Fourth Edition. 1994, Washington, DC:American Psychiatric Association.
 
7) 小阪憲司:アルツハイマー病の診断基準. 診断と治療 91:231-235, 2003.
Medical*Online
8) World Health Organization, The Icd-10 Classification of Mental and Behavioural Disorders:Clinical Descriptions and Diag-nostic Guidelines. 1992.
 
9) McKhann G, et al:Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (7):939-944, 1984.
 
10) Burns A, et al:Accuracy of clinicai diagnosis of Alzheimer's disease. BMJ 301 (6759):1026, 1990.
 
P.92 掲載の参考文献
1) Rosen W, et al:A new rating scale for Alzheimer's disease. Am J psychiatry 141:1356-1364, 1984.
 
2) Reisberg B, et al:Functional staging of dementia of the Alzheimer type. Ann NY Acad Sci 435:481-483, 1984.
 
3) Hughes C P, et al:Anew clinical scale for the staging of dementia. Br J psychiatry 140:566-572, 1982.
 
4) Sheikh J I, et al:Geriatric depression scale (GDS), recent evidence and development of a shorter version. Clin Gerontologist 5:165-173, 1986.
 
5) 浦上克哉, 他:アルツハイマー型痴呆の遺伝子多型と簡易スクリーニング法. 老年精医誌 13:5-10, 2002.
Medical*Online
6) 浦上克哉, 他:アルツハイマー病における塩酸ドネペジル (アリセプト) の使用経験-絵の描けるようになった著効例の報告-. 診療と新薬 37:1087-1091, 2000.
 
P.99 掲載の参考文献
1) Ritchie K, et al:Mild cognitive impairment:conceptual basis and current nosological status. Lancet 355 (9199):225-228, 2000.
PubMed
2) Flicker C, et al:Mild cognitive impairment in the elderly:predictors of dementia. Neurology 41 (7):1006-1009, 1991.
PubMed
3) Petersen R C, et al:Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273 (16):1274-1278, 1995.
PubMed
4) Petersen R C, et al:Mild cognitive impairment:clinical characterization and outcome. Arch Neurol 56 (3):303-308, 1999.
PubMed
5) Petersen R C, et al:Practice parameter:early detection of dementia:mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (9):1133-1142, 2001.
PubMed
6) Meguro K, et al:Prevalence and cognitive performances of clinical dementia rating 0.5 and mild cognitive impairment in Japan:The Tajiri Project. Alzheimer Dis Assoc Disord 18 (1):3-10, 2004.
 
7) Tierney M C, et al:Prediction of probable Alzheimer's disease in memory-impaired patients:Aprospective longitudinal study, Neurology 46 (3):661-665, 1996.
 
8) Devanand D P, et al:Questionable dementia:clinical course and predictors of outcome. J Am Geriant Soc 45 (3):321-328, 1997.
 
9) Daly E, et al:Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 57 (5):675-680, 2000.
PubMed
10) Ritchie K, et al:Classification criteria for mild cognitive impairment:a population based validation study. Neurology 56 (1):37-42, 2001.
PubMed
11) Jack CR Jr, et al:Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (7):1397-1403, 1999.
PubMed
12) Killiany R J, et al:Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 47 (4):430-439, 2000.
PubMed
13) Ishii K, et al:Glucose metabolic dysfunction in subjects with a clinical dementia rating of 0.5. J Neurol Sci 215 (1-2):71-74, 2003.
 
14) Johnson K A, et al:Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50 (6):1563-1571, 1998.
PubMed
15) Tanaka M, et al:Regional cerebral blood flow abnormalities in nondemented patients with memory impairment J Neuroimaging 12 (2):112-118, 2002.
PubMed
16) Galasko D:Cerebrospinal fluid opens a window on Alzheimer disease. Arch Neurol 56 (6):655-656, 1999.
PubMed
17) 松本圭司, 他:"もの忘れ外来"のための予備知識:MCIの予後. 精神科治療 17 (3):307-310, 2002.
 
P.105 掲載の参考文献
1) Ashburner J et al:Voxel-based morphometry:the methods. Neuroimage 11:805-821, 2000.
 
2) Ohnishi T et al:Changes in Brain Morphology in Alzheimer disease and normal aging:Is Alzheimer disease an exaggerated aging process? AJNR Am J Neuroradiol 22:1680-1685, 2001.
PubMed
3) Chetelat G et al:Mapping gray matter loss with voxe-based morphometry in mild cognitive impairement NeuroReport 13:1939-1943, 2002.
 
4) Matsuda H:Cerebral blood flow and meta-bolic abnormalities in Alzheimer's disease. Ann Nucl Med 15:85-92, 2001.
 
5) Silverman D H et al:Positron emission tomography in evaluation of dementia:Regional brain metabolism and long-term outcome. JAMA 286:2120-2127, 2001.
PubMed
6) Minoshima S et al:Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42:85-94, 1997.
PubMed
7) Kogure D et al:Longitudinal evaluation ofearly Alzheimer's disease using brain perfusion SPECT. J Nucl Med 41:1155-1162, 2000.
 
8) Chetelat G et al:Mild cognitive impairment:Can FDG-PET predict who is to rapidlyconvert to Alzheimer's disease? Neurology 60:1374-1377, 2003.
PubMed
9) Cabeza R et al:Similarities and differencesin the neural correlates of episodic memory retrieval and working memory. Neuroimage 16:317-330, 2002.
 
10) Neguro K et al:Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122:1519-1531, 1999.
 
11) Minoshima S et al:Alzheimer's disease versus dementia with Lewy bodies:cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50:358-365, 2001.
PubMed
P.113 掲載の参考文献
1) Kanai M, et al:Longitudinal study of cerebrospinal fluid levels of tau, AB1-40 and AB1-42 (43) in Alzheimer's disease:A Study in Japan. Ann Neurol 44 (1):17-26, 1998.
 
2) Shoji M, et al:Taps to Alzheimer's Patients:A continuous Japanese study of cerebrospinal fiuid biomarkers. Ann Neurol 48 (3):402, 2000.
 
3) Andreasen N, et al:Evaluation of CSF-tau and CSF-AB42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (3):373-379, 2001.
 
4) Kawarabayashi T, et al:Age-dependent changes in brain, CSF, and plasma amyloid B protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21 (2):372-381, 2001.
 
5) Strozyk D, et al:CSF AB42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (4):652-656, 2003.
 
6) Arai H, et al:Tau in cerebrospinal fluid:a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38 (4):649-652, 1995.
 
7) Shoji M, et al:Cerebrospinal fluid tau in dementia disorders:A large scale multicenter study by a Japanese study group. Neurobiol Aging 23 (3):363-370, 2002.
 
8) Clark C M, et al:Cerebrospinal fluid tau and B-amyloid:how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60 (12):1696-1702, 2003.
 
9) Ishiguro K, et al:Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 270 (2):91-94, 1999.
 
10) Itoh N, et al:Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50 (2):150-156, 2001.
 
11) Schoonenboom N S, et al:Amyloid β (1-42) and phosphorylated tau in CSF as markers for early-onset alzheimer disease. Neurology 62 (9):1580-1584, 2004.
 
12) Arai H, et al:Elevated cerebrospinal tau protein level as a predictor of dementia in memory-impaired individuals. Alzheimer's Res 3:211-213, 1997.
 
13) Buerger K, et al:CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 (4):627-629, 2002.
PubMed
14) Scheuner D, et al:Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 (8):864-870, 1996.
 
15) Mayeux R, et al:Plasma AB40 and AB42 and Alzheimer's disease:relation to age, mortality, and risk. Neurology 61 (9):1185-1190, 2003.
 
16) Matsubara E, et al:Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45 (4):537-541, 1999.
PubMed
P.122 掲載の参考文献
1) The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and National Institute on Aging Working Group. Consensus Report on:"Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 19 (2):107-167, 1998.
 
2) Gomez-Isla T, et al:Profbund loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16:4491-4500, 1996.
 
3) Shkmadzu H, et al Novel probes for imaging amyloid-B:F-18 and C-11 labellings of 2-(4-aminostyryl) benzoxazole derivatives. J Label Compd Radiopharm 47:181-190, 2004.
 
4) Okamura N, et al:Styrylbenzoxazole derivatives for in Vivo imaging of amyloid plaquesin the brain. J Neurosci 24:2535-2541, 2004.
 
5) Shoghi-Jadid K, et al:Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24-35, 2002.
PubMed
6) Klunk W E, et al:lmaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319, 2004.
 
7) Ono M, et al:11C-labeled stilbene derivatives as AB-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 30:565-571, 2003.
 
8) Verhoeff NPLG et al:Development of PET tracers for bata-amyloid imaging invivo. J Cereb Blood Flow Metab 23:S685, 2003.
 

第4章 アルツハイマー病の管理と治療

P.136 掲載の参考文献
1) Wada T, et al:Depression screening of Japanese community-dwelling elderly people. J Am Geriatr Soc, 2003 (in press).
 
2) Ho H K, et al:Factors associated with ADL dependence.-A comparative study of residential care home and community-dwelling older people in Japan. Geriatrics & Gerontology International 2:80-86, 2002.
 
3) Murashima S, et al:Characteristics of patients referred for discharge planning from ageriatric ward at a national university hospital in Japan:Implications for improving hospital programs. Nursing and Health Sciences 2 (3):153-161, 2001.
 
4) Masuda Y, et al:The effect of public long-term Care insurance plan on care management and care planning in Japanese geriatric hospitals, Arch Gerontol Geriat 32:167-177, 2001.
 
5) 竹内孝仁:痴呆症対策と介護保険導入の意義. 日本臨床増刊号 痴呆症学 (3), 307-311, 2004.
 
6) 遠藤英俊, 痴呆性高齢者のクリニカルパスと診断と治療に対する考え方. 痴呆性高齢者のクリニカルパス, p6-10. 日総研出版, 名古屋, 2004.
 
P.142 掲載の参考文献
1) 新井平伊:アルツハイマー型痴呆治療とアセチルコリン-Donepezil の薬効・薬理. 臨精薬理 3:1001-1008, 2000
 
2) Rogers S L, et al:Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease:an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8 (1):67-75, 1998
 
3) Doody P S, et al:Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (3):427-433, 2001.
 
4) Feldman H, et al:A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (4):613-620, 2001.
 
P.150 掲載の参考文献
1) 本間 昭:アルツハイマー型痴呆の治療とその実際. アルツハイマー型痴呆診断・治療マニュアル (アルツハイマー型痴呆診断・治療マニュアル製作委員会編), 129-162. 日本老年精神医学会, 東京, 2001.
 
2) Katz I R, et al:Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia:a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60:107-115, 1999.
 
3) De Deyn P P, et al:Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 19:115-126, 2004.
PubMed
4) Brodaty H, et al:A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia J Clin Psychiatry 64:134-143, 2003.
PubMed
5) Street J S, et al:Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities:a double-blind, randomized, placebo-controlled trial.The HGEU Study Group. Arch Gen Psychiatry 57:968-976, 2000.
 
6) Mulsant B H, et al:A twelve-week, double-blind, randomized comparison of nortripty-line and paroxetine in older depressed in-patients and outpatients. Am J Geriatr Psychiatry 9:406-414, 2001.
 
7) Dunner D L, et al:Optimal dose regimen for paroxetine. J Clin Psychiatry 53 Suppl 21-26, 1992.
 
P.157 掲載の参考文献
1) 李 飛, 他:方剤学. 中医薬学高級双書, 人民衛生出版社, 北京, 2002.
 
2) 王 新華, 他:中医基礎理論. 中医薬学高級双書, 人民衛生出版社, 北京, 2001.
 
3) 朱 文鋒, 他:中医診断学. 中医薬学高級双書, 人民衛生出版社, 北京, 1999.
 
4) Yabe T, et al:Choline acetyltransferase activity enhancing effects of kami-untan-to (KUT) on basal forebrain cultured neurons and lesioned rats. Phytomedicine 2:41-46, 1995.
PubMed
5) Yabe T, et al:Kami-untan-to (KUT) improves cholinergic deficits in aged rats. Phytomedicine 2:253-258, 1996.
PubMed
6) Suzuki T, et al:A Japanese herbal medicine (Kami-Untan-To) in the treatment of Alzheimer's disease:A pilot study. Alzheimer's Reports 4:177-182, 2001.
 
7) Iwasaki K, et al:Arandomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "Ba Wei Di Huang Wan" in the treatment of dementia. J Am Geriatr Soc in press.
 
8) Seki T, et al:Acupuncture for gait disorders in the elderly. J Am Geriatr Soc 52:643-644, 2004.
PubMed
9) Seki T, et al:Acupuncture and swallowing reflex in poststroke patients. J Am Geriatr Soc 51:726-727, 2003.
PubMed
P.164 掲載の参考文献
1) Hardy J, et al:The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297:353-356, 2002.
 
2) Schenk D, et al:Immunization with amyloid-B attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177, 1999.
 
3) Weiner HL, et al:Nasal administration of amyloid-b peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579, 2000.
 
4) Bard F, et al:Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919, 2000.
 
5) Janus C, et al:AB peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982, 2000.
 
6) Morgan D, et al:Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985, 2000.
 
7) Hock C, et al:Generation of antibodies specific for b-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270-1275, 2002.
 
8) Orgogozo J M, et al:Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization. Neurology 61:46-54, 2003.
 
9) Nicoll J A R, et al:Neuropathology of human Alzheimer disease after immunization with amyloid-b peptide:a case report. Nat Med 9:448-452, 2003.
 
10) Hock C, et al:Antibodies against B-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554, 2003.
 
11) DeMattos R B, et al:Peripheral anti-AB antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855, 2001.
 
12) DeMattos RB, et al:Brain to plasma amyloid-B efflux:a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267, 2002.
 
13) Matsuoka Y, et al:Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to B-amyloid. J Neurosci 23:29-33, 2003.
 
14) McLaurin J, et al:Therapeutically effective antibodies against amyloid-B peptide target amyloid-b residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-1269, 2002.
 
15) Frenkel D, et al:Immunization against Alzheimer's B-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 97:11455-11459, 2000.
 
16) Bard F, et al:Epitope and isotype specificities of antibodies to b-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028, 2003.
 
17) Monsonego A, et al:Increased T cell reactivity to amyloid b protein in older humans and patients with Alzheimer disease. J Clin Invest 112:415-422, 2003.
 
P.171 掲載の参考文献
1) American Psychiatric Association:Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 154 (Suppl 5):1-39, 1997.
 
2) Kazui H, et al:Impact of emotion on memory. Controlled study of the influence of emotionally charged material on declarative memory in Alzheimer's disease. Br J Psychiatry 177 (10); 343-347, 2000.
 
3) 谷向 知, 他:痴呆の認知障害. 新世紀の精神科治療第6巻「認知の科学と臨床」(武田雅俊 編), pp103-115, 中山書店, 東京, 2003.
 
4) Butler R N:The life review:An interpretation of reminiscence in the aged. Psychiatry 26:65-75, 1963.
PubMed
5) 黒川由紀子:痴呆老人に対する回想法グループ. 老年精神医学雑誌 5 (1):73-81, 1992.
 
6) 奥村由美子, 他:回想法による短期入院痴呆性高齢者への効果と介護スタッフにもたらす介護意識・ストレスに関する研究. 平成14年度三井住友海上福祉財団研究助成団報告書, 2004. (印刷中)
 
7) Feil N:Validation:An empathic approach to the care of dementia. Clin Geron trol 8:89-94, 1989.
 
8) Folsom J C:Reality orientation for the elderly mental patient. J Geriatr Psychiatry 1:291-305, 1968
 
9) 松岡恵子, 他:非薬物療法がアルツハイマー型痴呆患者の認知機能に及ぼす効果; 予備的検討. 老年精医誌 13 (8):929-936, 2002.
Medical*Online
10) Brotons M, et al:The impact of music therapy on language functioning in dementia. J Music Ther 37 (3):183-195, 2000
PubMed
11) Corson S A, et al:Pet dogs as nonverbal communication links in hospital psychiatry. Compr Psychiatry 18 (1):61-71, 1977.
PubMed
12) 真野充弘, 他:痴呆性高齢者に対するドッグセラピーの試み. 日本痴呆ケア学会誌 2 (2):150-157, 2003.
Medical*Online
13) 谷向 知, 他:テレビ番組が与える痴呆性高齢者への影響に関する研究. 平成12年度老人健康増進等事業による研究報告書:16-19, 2001.
 
14) 今井幸充:痴呆の非薬物療法の概念-レクレーションとの区別のために-. 老年社会科学 26 (1):5-14, 2004.
 
P.179 掲載の参考文献
1) Schulz R, et al:Caregiving as a risk factor for mortality. JAMA 282 (23):2215-2219, 1999.
PubMed
2) Zarit S H, et al:Relatives of the impaired elderly:Correlates of feelings of burden. Gerontologist 20:649-655, 1980.
PubMed
3) Zarit S H, et al:The Memory and Behaviour Problems Checklist 1987R and the Burden Interview. Pennsylvania State University Gerontology Center. University Park, PA, 1990.
 
4) Arai Y, et al:Reliability and validity of the Japanese version of the Zarit Caregiver Burden Interview. Psychiatry Clin Neurosci 51:281-287, 1997.
PubMed
5) 荒井由美子, 他:Zarit 介護負担尺度日本語版の短縮版 (J-ZBI_8) の作成:その信頼性と妥当性に関する検討. 日老医誌 40 (5):471-477, 2003.
 
6) Kumamoto K, et al:Validation of "Personal Strain" and "Role Strain":Subscales of the short version of the Japanese version of the Zarit Burden Interview (J-ZBI_8). Psychiatry Clin Neurosci 58 (6), 2004. (in press)
 
7) 熊本圭吾, 他:日本語版 Zarit 介護負担尺度短縮版 (J-ZBI_8) の交差妥当性の検討. 日老医誌 41 (2):204-210, 2004.
 
8) Arai Y, et al:Are there inequities in the assessment of dementia under Japan's LTC insurance system? Int J Geriatr Psychiatry 18:346-352, 2003.
PubMed
9) Arai Y, et al:Burden felt by family caring for the elderly members needing care in southern Japan. Aging Ment Health 3:158-164, 1999.
 
10) Arai Y, et al:Factors related to feelings of burden among caregivers looking after impaired elderly in Japan under the Long-Term Care Insurance system. Psychiatry Clin Neurosci 58 (4):396-402, 2004.
 
11) Herbert R, et al:Efficacy of a psychoeducative group program for caregivers of demented persons living at home:a randomized controlled trial. J Gerontol B-Psychol 58B:S58-S67, 2003.
 
12) Miller B, et al:Social support and caregiver distress:A replication analysis. J Gerontol B-Psychol 56B:249-S256, 2001.
 
13) Arai Y, et al:Undue concern for other's opinions deters caregivers of impaired elderly from using public services in rural Japan. Int J Geriatr Psychiatry 15:961-968, 2000.
 
P.187 掲載の参考文献
1) 室伏君士, 他:アルツハイマー型老年痴呆の症状と診断, 老年期精神疾患の症状と診断. 老年精医誌 1 (3):304-314, 1990.
 
2) 高松淳一, 他:痴呆のリハビリテーション-経時的アプローチ-, 痴呆症のすべて (平井俊策編), p201-211. 永井書店, 東京, 2000.
 
3) 長谷川和夫, 他:老化性痴呆の追跡調査5年後の予後. 日老医誌 17:630-638, 1980.
 
4) Walsh J S, et al:Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 113 (6):429-434, 1990.
PubMed
5) Larson E B, et al:Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140 (7):501-509, 2004.
PubMed
6) Molsa PK, et al:Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 74:103-107, 1986.
PubMed
7) Barclay L L, et al:Factors associated with duration of survival in Alzheimer's disease. Biol Psychiatry 20 (1):86-93, 1985.
 
8) Mortimer J A, et al:Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42 (9):1689-1696, 1992.
PubMed
9) Yamada T, et al:Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. J Neurol Sci 129:56-61, 1995.
 
10) Drachman DA, et al:The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course. Arch Neurol 47 (8):851-856, 1990.
PubMed
11) Cummings J L, et al:Dementia:a clinical approach, p. 38, Butterworth, Boston, 1983.
 
12) Piccini C, et al:Natural history of Alzheimer's disease:prognostic value of plateaux. Neurol Sci 131 (2):177-182, 1995.
PubMed
13) Reisberg B, et al:Longitudinal course ofnormal aging and progressive dementia ofthe Alzheimer's type:a prospective studyof 106 subjects over a 3.6 year mean interval. Prog Neuropsychopharmacol Biol Psychiatry 10 (3-5):571-578, 1986.
 
14) Reisberg B, et al:Senile dementia of Alzheimer type; diagnostic and differential diagnostic features with special referenceto functional assessment of staging. ln:(Traber J, et al, eds) Senile dementia of Alzheimer type; early diagnosis, neuropathology and animal models, p18-37, Springer, Berlin, 1985.
 
15)Magni E, et al:Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 9 (3):123-126, 1996.
PubMed
16)Forstl H, et al:Psychiatric features and thecourse of Alzheimer's disease:relationshipto cognitive, electroencephalographic andcomputerized tomography findings. Acta Psychiatr Scand 87 (6):395-399, 1993.
 
17)Baker F M, et al:Delirium episodes during the course of clinically diagnosed Alzheimer's disease. J Natl Med Assoc 91 (11):625-630, 1999.
 
18) Koopmans R T, et al:The course of Alzheimer's disease in a group of nursing home patients:epidemiology, (co) mobidity and mortality. Ned Tijdschr Geneeskd 135 (19):845-850, 1991.
 
19) Stern Y, et al:Predictors of disease course in patients with probable Alzheimer's disease. Neurology 37 (10):1649-1653, 1987.
PubMed
20) Samson W N, et al:Clinical features and mortality in patients with early-onset Alzheimer's disease. Eur Neurol 36 (2):103-106, 1996.
PubMed
21) Mann UM, et al:Heterogeneity in Alzheimer's disease:progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry 55 (10):956-959, 1992.
 
22) Nobili F, et al:Timing of disease progression by quahtitative EEG in Alzheimer's patients. J Clin Neurophysiol 16 (6):566-573, 1999.
PubMed
23) Kukull W A, et al:Cause of death associated with Alzheimer disease:variation by level of cognitive impairment before death. J Am Geriatr Soc 42 (7):723-726, 1994.
 
24) McCormick W C, et al:Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc 42 (5):517-521, 1994.
 
25) Lopez O L, et al:Psychiatric medication and abnormal behavior as predictors of of progression in probable Alzheimer disease. Arch Neurol 56 (10):1266-1272, 1999.
PubMed
26) Annerstedt L:An attempt to determine the impact of group living care in comparison to traditional long-term care on demented elderly patients. Aging (Milano) 6 (5):372-380, 1994.
PubMed
P.200 掲載の参考文献
1) 痴呆性高齢者対策:痴呆問題の今とこれから (座談会), 厚生労働 59:5-11, 2004.
 
2) 2000 Progress report on Alzheimer disease. Introduction 2-5, NIH, 2000.
 
3) Hebert L E, et al:Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzhemier Dis Assoc 15:169-173, 2001.
 
4) Ernst R L, et al:Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol 54:687-693, 1997.
PubMed
5) AD 2000 Collaborative Group:Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000):randomized double-blind trial. Lancet 363:2105-2015, 2004.
 
6) 英国バーミンガム大学を中心に実施された AD2000 臨床試験結果について, エーザイホームページ (http://www.eisai.co.jp/news/news24-27.html)
 
7) Canadian Coordinating Oce for Health Technology Assessment:Guidelines for Economic Evaluation of Pharmaceuticals, Canada, 1997.
 

第5章 アルツハイマー病治療ガイドライン

P.210 掲載の参考文献
1) 中村重信, 他:痴呆疾患治療ガイドライン. 臨神経 42:781-833, 2002.
 
2) 中村重信 編:痴呆疾患の治療ガイドライン. ワールドプラニング, 東京, 2003.
 
3) Nakamura S:Aguideline for the treatment of dementia in Japan. Int Med 43:18-29, 2004.
 
4) 中村重信:痴呆疾患治療ガイドラインのフローチャート. 臨神経 44:211-212, 2004.
 
5) American Psychiatric Association:Practice guideline for the treatment of patients with Alzheimer disease and other dementias of late life. APA, Washington, 1997,
 
6) Doody R S, et al:Practice parameter:management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1154-1166, 2001.
PubMed
7) Homma A, et al:Clinical efficacy and safety of donepezil on cognitive and global functionin patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebocontrolledstudy in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 11:299-313, 2000.
 
8) Feldman H, et al:A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57:613-620, 2001.
 
9) Birks J, et al:Rivastigmine for Alzheimer's disease. Cochrane Library, 2001.
 
10) Olin J, et al:Galantamine for Alzheimer's disease. Cochrane Library, 2001.
 

書評

最近チェックした商品履歴

Loading...